With U.S. sales topping $750 million, GSK launches ambitious campaign touting benefits of its fish oil drug
Jun. 1, 2010 12:00pm
It's been a banner year for the makers of Lovaza. The world's first prescription omega-3 fatty acid — manufactured by Norway-based Pronova Biopharma and marketed in the United States by GlaxoSmithKline (GSK) — reached “blockbuster” status in 2009, with global sales topping $1 billion and U.S. sales reaching $758 million, according to market research firm IMS Health. Thus far this year, international sales are up another 9%. And thanks to an ambitious multimillion-dollar TV and print campaign that not-so-subtly emphasizes “you can't get it in a health food store,” sales are...
Sign in to view
the full article
This article is part of our paid subscription packages. You need to subscribe (and sign in) to gain access to this Subscriber Only Content.
Why Subscribe to Nutrition Business Journal?
- In-depth perspective on the $226 billion global nutrition industry
- Receive monthly issues and access up to 5 years of back issues
- Downloadable data files, presentations, and more
Register Here to complete step one of the Premium Content subscription process